Haleon PLC Advances Share Buyback Program with Recent Share Repurchase

An announcement from Haleon PLC ( (GB:HLN) ) is now available.

Haleon PLC has announced the repurchase of 971,129 ordinary shares as part of its ongoing share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic focus on optimizing its capital structure and enhancing shareholder value, with the current registered share capital standing at nearly 9 billion ordinary shares.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects strong financial performance and positive corporate actions like share buybacks, though tempered by a high valuation and mixed technical indicators. The company’s strategic focus on innovation and expansion in emerging markets supports future growth prospects.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across six major categories, including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands, such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, are recognized for their trusted science and innovation.

Average Trading Volume: 27,309,333

Technical Sentiment Signal: Buy

Current Market Cap: £35.73B

For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.